Stock ARDX ARDELYX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ardelyx, Inc.

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
6.61 USD +3.28% Intraday chart for Ardelyx, Inc. +2.80% +6.61%
04-17 Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating MT
04-05 Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target MT

Business Summary

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Number of employees: 267

Sales per Business

USD in Million2022Weight2023Weight Delta
Biopharmaceutical Products
100.0 %
52 100.0 % 124 100.0 % +138.61%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
66.9 %
16 29.9 % 83 66.9 % +433.82%
Asia Pacific
33.0 %
37 70.0 % 41 33.0 % +12.58%
North America
0.0 %
0 0.1 % 0 0.0 % +90.32%

Managers

Managers TitleAgeSince
Mike Raab Raab CEO
 Chief Executive Officer 59 28/02/09
Justin Renz DFI
 Director of Finance/CFO 52 08/06/20
Laura Williams CTO
 Chief Tech/Sci/R&D Officer 61 31/10/20
Elizabeth Grammer ADM
 Chief Administrative Officer 60 30/11/12
Caitlin Lowie IRC
 Investor Relations Contact - 31/10/22
Charon Spencer HRO
 Human Resources Officer - 31/12/22
Robert Felsch AUD
 Comptroller/Controller/Auditor - 31/01/22
David Rosenbaum PRN
 Corporate Officer/Principal 63 31/12/09
Susan Rodriguez PRN
 Corporate Officer/Principal 60 17/05/20
Robert Blanks LAW
 General Counsel 64 31/07/13

Members of the board

Members of the board TitleAgeSince
William Bertrand BRD
 Director/Board Member 59 25/10/15
Richard Rodgers BRD
 Director/Board Member 57 28/02/14
David Mott CHM
 Chairman 58 28/02/09
Jan Lundberg BRD
 Director/Board Member 70 22/03/18
Mike Raab Raab CEO
 Chief Executive Officer 59 28/02/09
Onaiza Cadoret-Manier BRD
 Director/Board Member 60 11/03/20
Robert B. Bazemore BRD
 Director/Board Member 56 01/06/16
Muna Bhanji BRD
 Director/Board Member 61 10/03/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 233,976,572 229,730,216 ( 98.19 %) 0 98.19 %

Shareholders

NameEquities%Valuation
Janus Henderson Investors US LLC
10.60 %
24,658,820 10.60 % 180 M $
STATE STREET CORPORATION
7.350 %
17,102,598 7.350 % 125 M $
BlackRock Advisors LLC
6.828 %
15,887,439 6.828 % 116 M $
Vanguard Fiduciary Trust Co.
5.598 %
13,026,046 5.598 % 95 M $
Eventide Asset Management LLC
2.925 %
6,805,494 2.925 % 50 M $
Geode Capital Management LLC
2.147 %
4,995,362 2.147 % 36 M $
Rubric Capital Management LP
1.725 %
4,012,753 1.725 % 29 M $
Morgan Stanley Investment Management, Inc.
1.377 %
3,205,108 1.377 % 23 M $
KYOWA KIRIN CO. LTD.
1.235 %
2,873,563 1.235 % 21 M $
Adage Capital Partners GP LLC
1.117 %
2,600,000 1.117 % 19 M $

Company contact information

Ardelyx, Inc.

400 Fifth Avenue Suite 210

02451, Waltham

+510 745 1700

http://www.ardelyx.com
address Ardelyx, Inc.(ARDX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Ardelyx, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
6.61 USD
Average target price
13.39 USD
Spread / Average Target
+102.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARDELYX, INC. Stock Ardelyx, Inc.
+6.61% 1.55B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+4.92% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-8.65% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARDX Stock
  4. Company Ardelyx, Inc.